TraceLink Inc., the leader in protecting patient safety and enabling health for global Life Sciences, today announced that it has expanded its Board of Directors with the appointment of three new business executives. The newly appointed directors bring decades of experience to TraceLink in financial operations, SaaS solutions, big data, risk management, security, and corporate governance, and each will play a key leadership role as the company continues to penetrate the global marketplace in the category-leading position of track and trace solutions for the Life Sciences industry. The three new directors are:
- Sean Cantwell, partner at Volition Capital, the leading investment firm behind TraceLink’s recent growth financing of $20M . Cantwell’s broad experience in SaaS and technology-enabled services businesses includes directorships and/or investments in Visual IQ, iPipeline, G5 Search Marketing, GlobalTranz, Ping Identity, and The Resumator. Prior to Volition, Cantwell held leadership positions at Fidelity Ventures, Summit Partners and Arthur Andersen.
- Thomas Ebling, president, CEO, and chairman of the board of Demandware. Ebling’s tenure at Demandware began as a board director 2006 while he was serving as CEO of Lattice Engines. Prior to Lattice Engines, Ebling served as CEO and Chairman of the Board of Directors of ProfitLogic, Inc., which was acquired by Oracle. He has also served as CEO of data warehousing and analytics provider, Torrent Systems, Inc., and previously held a range of leadership positions at software applications company, Marcam Solutions, Inc.
- Jennifer Ley, Director of Enterprise Risk Intelligence at Target Corporation. In her current role, Ley is responsible for the identification, assessment and prioritization of risks for Target, namely in the areas of global security, governance, reputation, fraud, healthcare, and business intelligence and analytics. Prior to Target, Ley was a senior executive with the Federal Bureau of Investigation (FBI), and while serving as Deputy Assistant Director, was responsible for all strategic and operational intelligence for counterterrorism. Prior to the FBI, Ley worked for the Department of Commerce in the International Trade Administration. She currently holds a board director position at the Retail Cyber Intelligence Sharing Center (R-CISC).
“Sean, Tom and Jenny are talented, versatile business leaders who will provide TraceLink with invaluable perspective on our growth plans, management operations, and overall strategic direction,” said Shabbir Dahod, president and CEO of TraceLink. “As we continue to build on our recent successes helping global Life Sciences companies to comply with regulations that protect patients from counterfeit drugs, I look forward to the collective wisdom and experience they will lend to our ability to deliver the products, services and support our customers need to achieve success. We welcome them to the TraceLink Board.”
The appointments of Cantwell, Ebling and Ley bring the total number of TraceLink board members to six, complementing existing directors Lawrence D. Lenihan, founder and managing director of FirstMark Capital; Jack M. Cooper, founder and CEO of JM Cooper and Associates, and former CIO of Bristol-Myers Squibb, J. E. Seagram and CSX; and Shabbir Dahod, president and CEO of TraceLink.
New Strategic Advisory Board Provides Additional Guidance
TraceLink has also announced the formation of a strategic advisory board that includes select industry leaders with distinguished accomplishments in pharmaceuticals, supply chain management, mechanical design and engineering, and regulatory compliance. Current members of the TraceLink advisory board include:
- Sanjay Sarma—MIT professor and Dean of Digital Learning, and author of RFID Technology and Applications as well as over two dozen papers on RFID. Sarma is also a current member of GS1 US Board of Governors, the 2010 recipient of the RFID Journal Special Achievement Award, and holder of a dozen US patents, including patents on RFID security, sensing and tracking.
- Peter Bigelow—current president of xCell Strategic Consulting, a firm that serves the pharmaceutical industry. Bigelow formerly held the roles of both president and CEO of North America Commercial Operations at Patheon Pharmaceuticals, and served in executive positions at Wyeth Pharmaceuticals (now Pfizer), and SmithKline Beecham (now GlaxoSmithKline). He is a current member of the International Leadership Forum of the International Society for Pharmaceutical Engineering (ISPE), and board member of IPS, a Global Engineering Services Company.
“Sanjay and Peter are deeply entrenched in the challenges and opportunities facing Life Sciences companies,” added Dahod. “Their industry insight and knowledge will be an asset to TraceLink as we continue building the only open network platform that allows global pharmaceutical supply chain partners to connect, exchange data and achieve regulatory compliance everywhere in the world.”
To learn more about how TraceLink is helping Life Sciences companies meet global pharmaceutical compliance deadlines as well as how to build a flexible global serialization, track and trace, and reporting platform for Brazil, China and other countries, visit www.tracelink.com.